Roth Capital Downgrades Cyclacel Pharmaceuticals (CYCC) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 41
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 41
Join SI Premium – FREE
Roth Capital downgraded Cyclacel Pharmaceuticals (NASDAQ: CYCC) from Buy to Neutral with a price target of $1.00.
For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $0.73 yesterday.
For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $0.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CLSA Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Hold (3)
- Canaccord Downgrades OFX Group Ltd (OFX:AU) to Hold
- Raymond James Downgrades USCB Financial holdings (USCB) to Outperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
